Global action plan for influenza vaccines

OBJECTIVE 2. Increase in vaccine production capacity

The second GAP approach concentrates on increasing production capacity for pandemic vaccines without expectation for a commensurate increase in the demand for seasonal vaccine.


WHO/Olivier Asselin

By 2015, produce enough vaccine to immunize two billion people; this vaccine should be available on the market six months after transfer of the vaccine prototype strain to vaccine manufacturers.

Medium and long term goal: produce enough vaccine to immunize 70% o fthe world's population with two doses, in 6 months after transfer of the vaccine prototype strain to vaccine manufacturers.
To assist Member States respond to pandemic, WHO is promoting:
- the expansion of existing influenza vaccine capacity as well as the establishment of new production capacity in countries and regions previously lacking such capacity and
-the use of high-yield technologies to enable surge capacity in the event of the pandemic.


  • Seasonal influenza vaccine production capacity has increased globally from less than 500 million doses per year in 2006 to close to 1 billion doses per year at the end of 2010.
  • 14 developing countries have been awarded grants to establish in-country manufacturing capacity for influenza vaccine: Brazil, China, Egypt, India, Indonesia, Iran, Kazakhstan, Mexico, Republic of Korea, Romania, Serbia, South Africa, Thailand and Viet Nam. Of these manufacturers, five currently have a licensed vaccine on the market (India, Indonesia, Romania, Republic of Korea and Thailand) and the remaining are in late stage development. Financial support has been provided by the Department of Health & Human Services of the USA, the Government of Japan, the Asian Development Bank, the Government of Canada and the UK Government.
  • WHO facilitated the creation of a "technology transfer hub" at the Netherlands Vaccine Institute (RIVM) to provide training in the production of inactivated influenza vaccine produced in embryonated eggs. Many grantees have received training through this hub. A similar hub at the University of Lausanne is currently providing training in the production of adjuvants for pandemic influenza vaccines. Indonesia is currently receiving technology transfer from this hub.

Background information:

GAP I, 2-3 May 2006, Geneva

GAP II, 12-14 July 2011, Geneva

Topics of interest suggested for discussion in working groups:

  • progress in increasing production capacity by region
  • vaccine production barriers and capacities of manufactures
  • sustainability of global influenza vaccine production
  • new production methods and convertible systems